Telomir Pharmaceuticals (TELO) News Today → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free TELO Stock Alerts $6.91 +0.37 (+5.66%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinemarketbeat.com - April 22 at 11:35 AMTelomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.globenewswire.com - April 16 at 8:30 AMTelomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024globenewswire.com - April 2 at 8:30 AMUPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Caninesglobenewswire.com - March 29 at 4:44 PMTelomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Caninesglobenewswire.com - March 26 at 8:30 AMTelomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26thglobenewswire.com - March 22 at 8:30 AMTelomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Scienceglobenewswire.com - March 14 at 8:30 AMTelomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conferenceglobenewswire.com - March 7 at 8:30 AMTelomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conferenceglobenewswire.com - March 7 at 8:30 AMMichael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversalglobenewswire.com - March 5 at 8:30 AMmarketbeat.com - February 20 at 10:09 AMmarketbeat.com - February 14 at 3:31 PMmarketbeat.com - February 14 at 3:14 PMmarketbeat.com - February 14 at 2:28 PMmarketbeat.com - February 14 at 2:11 PMmarketbeat.com - February 14 at 1:53 PMmarketbeat.com - February 12 at 1:34 PMmarketbeat.com - February 9 at 11:14 AMmarketbeat.com - February 9 at 11:04 AMmarketbeat.com - February 9 at 10:51 AM Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. TELO Media Mentions By Week TELO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TELO News Sentiment▼1.890.52▲Average Medical News Sentiment TELO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TELO Articles This Week▼11▲TELO Articles Average Week Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Lifecore Biomedical News Veru News Galectin Therapeutics News Acrivon Therapeutics News Organigram News Trevi Therapeutics News Omeros News Greenwich LifeSciences News Rigel Pharmaceuticals News Alimera Sciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TELO) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchGold Set to EXPLODE!Gold Safe ExchangeHow Biden has already won 2024Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.